

John Lally

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8635384/publications.pdf>

Version: 2024-02-01

92
papers

3,266
citations

236612

25
h-index

161609

54
g-index

94
all docs

94
docs citations

94
times ranked

4724
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. <i>World Psychiatry</i> , 2016, 15, 166-174.	4.8	487
2	Antipsychotic medication in schizophrenia: a review. <i>British Medical Bulletin</i> , 2015, 114, 169-179.	2.7	356
3	Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. <i>British Journal of Psychiatry</i> , 2017, 211, 350-358.	1.7	239
4	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. <i>Psychological Medicine</i> , 2016, 46, 3231-3240.	2.7	202
5	Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2016, 171, 215-224.	1.1	130
6	Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. <i>BMC Medicine</i> , 2016, 14, 189.	2.3	119
7	Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. <i>Psychological Medicine</i> , 2015, 45, 2619-2629.	2.7	110
8	Stigma of mental illness and help-seeking intention in university students. <i>The Psychiatrist</i> , 2013, 37, 253-260.	0.3	87
9	Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 863.	1.8	85
10	Vitamin D deficiency in first episode psychosis: A case-control study. <i>Schizophrenia Research</i> , 2013, 150, 533-537.	1.1	76
11	Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, Volume 9, 117-129.	0.4	69
12	Uncertainty and Ambiguity and Their Association with Psychological Distress in Medical Students. <i>Academic Psychiatry</i> , 2014, 38, 339-344.	0.4	58
13	Substance use, medication adherence and outcome one year following a first episode of psychosis. <i>Schizophrenia Research</i> , 2016, 170, 311-317.	1.1	55
14	Mental health services in the Philippines. <i>BJPsych International</i> , 2019, 16, 62-64.	0.8	47
15	Clinical correlates of vitamin D deficiency in established psychosis. <i>BMC Psychiatry</i> , 2016, 16, 76.	1.1	44
16	Increases in triglyceride levels are associated with clinical response to clozapine treatment. <i>Journal of Psychopharmacology</i> , 2013, 27, 401-403.	2.0	40
17	Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPACT). <i>BMC Psychiatry</i> , 2017, 17, 413.	1.1	39
18	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. <i>Schizophrenia Bulletin</i> , 2021, 47, 662-671.	2.3	39

#	ARTICLE	IF	CITATIONS
19	Treatment resistant schizophrenia – review and a call to action. Irish Journal of Psychological Medicine, 2019, 36, 279-291.	0.7	37
20	Correlates of vitamin D in psychotic disorders: A comprehensive systematic review. Psychiatry Research, 2017, 249, 78-85.	1.7	34
21	Clozapine in the treatment of refractory schizophrenia: a practical guide for healthcare professionals. British Medical Bulletin, 2020, 135, 73-89.	2.7	34
22	The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge. Journal of Clinical Psychopharmacology, 2017, 37, 600-604.	0.7	33
23	Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophrenia Research, 2018, 195, 267-273.	1.1	32
24	Improving physical health and reducing substance use in psychosis – randomised control trial (IMPACT RCT): study protocol for a cluster randomised controlled trial. BMC Psychiatry, 2013, 13, 263.	1.1	28
25	Lower Bone Mineral Density at the Hip and Lumbar Spine in People with Psychosis Versus Controls: a Comprehensive Review and Skeletal Site-Specific Meta-analysis. Current Osteoporosis Reports, 2016, 14, 249-259.	1.5	28
26	Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. Schizophrenia Research, 2017, 189, 117-125.	1.1	28
27	Predictors of falls and fractures leading to hospitalization in people with schizophrenia spectrum disorder: A large representative cohort study. Schizophrenia Research, 2018, 201, 70-78.	1.1	27
28	Differential gene expression analysis in blood of first episode psychosis patients. Schizophrenia Research, 2019, 209, 88-97.	1.1	27
29	Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Psychopharmacology, 2017, 37, 441-446.	0.7	26
30	Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 1101-1111.	1.6	26
31	Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis. British Journal of Psychiatry, 2015, 206, 164-165.	1.7	25
32	Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. British Journal of Psychiatry, 2019, 215, 712-719.	1.7	25
33	Tobacco smoking and nicotine dependence in first episode and established psychosis. Asian Journal of Psychiatry, 2019, 43, 125-131.	0.9	25
34	Employment and relationship outcomes in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophrenia Research, 2021, 231, 122-133.	1.1	25
35	Hepatitis, Interstitial Nephritis, and Pancreatitis in Association With Clozapine Treatment. Journal of Clinical Psychopharmacology, 2018, 38, 520-527.	0.7	24
36	Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey. Psychiatry Research, 2019, 275, 155-161.	1.7	24

#	ARTICLE	IF	CITATIONS
37	Increased rates of respiratory disease in schizophrenia: A systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls. <i>Schizophrenia Research</i> , 2021, 237, 131-140.	1.1	23
38	Brain-relevant antibodies in first-episode psychosis: a matched caseâ€“control study. <i>Psychological Medicine</i> , 2018, 48, 1257-1263.	2.7	22
39	The Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial. <i>Frontiers in Psychiatry</i> , 2018, 9, 654.	1.3	22
40	Hospitalisation and length of hospital stay following first-episode psychosis: systematic review and meta-analysis of longitudinal studies. <i>Psychological Medicine</i> , 2020, 50, 991-1001.	2.7	22
41	Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 3045-3054.	1.5	20
42	Mental health legislation in the Philippines: Philippine Mental Health Act. <i>BJPsych International</i> , 2019, 16, 65-67.	0.8	20
43	Prevalence study of head shop drug usage in mental health services. <i>The Psychiatrist</i> , 2013, 37, 44-48.	0.3	17
44	Patient satisfaction with psychiatric outpatient care in a university hospital setting. <i>Irish Journal of Psychological Medicine</i> , 2013, 30, 271-277.	0.7	16
45	Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. <i>Schizophrenia Research</i> , 2018, 197, 294-297.	1.1	16
46	Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. <i>Schizophrenia Research</i> , 2019, 204, 381-388.	1.1	16
47	Structural Covariance of Cortical Gyri-fication at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses. <i>Schizophrenia Bulletin</i> , 2021, 47, 1729-1739.	2.3	16
48	Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 117-122.	1.2	15
49	Acute hospital service utilization by inpatients in psychiatric hospitals. <i>General Hospital Psychiatry</i> , 2015, 37, 577-580.	1.2	14
50	Rechallenge Following Clozapine-Associated Eosinophilia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 504-506.	0.7	13
51	Autoantibodies against voltageâ€“gated potassium channel and glutamic acid decarboxylase in psychosis: <scp>A</scp> systematic review, metaâ€“analysis, and case series. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 678-689.	1.0	13
52	Serum Prolactin and Bone Mineral Density in Schizophrenia: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 333-342.	0.9	13
53	Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 411-424.	1.3	12
54	Predicting onset of early- and late-treatment resistance in first-episode schizophrenia patients using advanced shrinkage statistical methods in a small sample. <i>Psychiatry Research</i> , 2020, 294, 113527.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Metabolic syndrome in patients attending psychiatric day centres: prevalence and associations. <i>The Psychiatrist</i> , 2012, 36, 326-331.	0.3	10
56	Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPACT): cost-effectiveness of integrated psychosocial health promotion. <i>BMC Psychiatry</i> , 2017, 17, 407.	1.1	10
57	Clozapine Rechallenge Following Neuroleptic Malignant Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 372-379.	0.7	10
58	Pharmacological interventions for clozapine-induced sinus tachycardia. <i>The Cochrane Library</i> , 2016, 2016, CD011566.	1.5	9
59	Personalised approaches to pharmacotherapy for schizophrenia. <i>BJ Psych Advances</i> , 2016, 22, 78-86.	0.5	9
60	Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. <i>Psychopharmacology</i> , 2020, 237, 443-451.	1.5	9
61	Augmentation of clozapine with ECT: a retrospective case analysis. <i>Acta Neuropsychiatrica</i> , 2021, 33, 31-36.	1.0	9
62	Mental disorders in Malaysia: an increase in lifetime prevalence. <i>BJPsych International</i> , 2021, 18, 97-99.	0.8	9
63	Simple Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2019, 207, 721-725.	0.5	8
64	Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosis. <i>Schizophrenia Research</i> , 2018, 193, 391-398.	1.1	7
65	Severe Neutropenia and Agranulocytosis. , 2016, , 105-148.		6
66	Successful clozapine re-challenge in a patient with three previous episodes of clozapine-associated blood dyscrasia. <i>BJPsych Open</i> , 2017, 3, 22-25.	0.3	6
67	Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review. <i>General Hospital Psychiatry</i> , 2020, 67, 83-91.	1.2	6
68	Real-World Outcomes in the Management of Refractory Psychosis. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	6
69	Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. <i>NPJ Schizophrenia</i> , 2022, 8, 13.	2.0	6
70	A case of paliperidone-palmitate-induced tardive dyskinesia. <i>General Hospital Psychiatry</i> , 2013, 35, 213.e5-213.e7.	1.2	5
71	Clozapine augmentation for treatment-resistant schizoaffective disorder. <i>The Cochrane Library</i> , 0, , .	1.5	5
72	Vitamin D in schizophrenia and depression: a clinical review. <i>BJ Psych Advances</i> , 2019, 25, 240-248.	0.5	5

#	ARTICLE	IF	CITATIONS
73	Vitamin D deficiency in schizophrenia implications for COVID-19 infection. Irish Journal of Psychological Medicine, 2021, 38, 278-287.	0.7	5
74	Prevalence of hypercalcaemia in patients on maintenance lithium therapy monitored in primary care. Irish Medical Journal, 2013, 106, 15-7.	0.0	5
75	Lipids and polyunsaturated fatty acid levels in deliberate self-harm: a 10-year follow-up study. Irish Journal of Psychological Medicine, 2017, 34, 117-126.	0.7	4
76	Management of lithium intoxication. BJ Psych Advances, 2023, 29, 82-91.	0.5	4
77	Refractory mania and inability to consent: an important role for involuntary ECT. Irish Journal of Psychological Medicine, 2013, 30, 73-76.	0.7	3
78	Follow-up study of 6.5 years of admissions to a UK female medium secure forensic psychiatry unit. BJPsych Bulletin, 2019, 43, 54-57.	0.7	3
79	Admission patterns in a psychiatric intensive care unit in Ireland: a longitudinal follow-up. Irish Journal of Psychological Medicine, 2023, 40, 361-368.	0.7	3
80	A health promotion intervention to improve lifestyle choices and health outcomes in people with psychosis: a research programme including the IMPaCT RCT. Programme Grants for Applied Research, 2020, 8, 1-124.	0.4	3
81	Liberty or dignity: community treatment orders and rights. Irish Journal of Psychological Medicine, 2013, 30, 141-149.	0.7	2
82	Are psychiatric team meetings patient centred? A cross-sectional survey on patient views regarding multi-disciplinary team meetings. Irish Journal of Psychological Medicine, 2015, 32, 177-185.	0.7	2
83	Remission and recovery from first-episode psychosis in adults: A systematic review and meta-analysis of long-term outcome studies. European Psychiatry, 2017, 41, s819-s819.	0.1	2
84	“Legal highs” – what's in a name?. BJPsych Bulletin, 2015, 39, 206-206.	0.7	1
85	Takotsubo syndrome in bipolar affective disorder with alcohol withdrawal syndrome. BMJ Case Reports, 2020, 13, e236070.	0.2	1
86	Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?. NPJ Schizophrenia, 2015, 1, 15036.	2.0	0
87	O5.2. PREDICTORS OF CARDIOMETABOLIC RISK IN THE YEAR AFTER ONSET OF PSYCHOSIS: A PROSPECTIVE COHORT STUDY. Schizophrenia Bulletin, 2018, 44, S87-S87.	2.3	0
88	S123. TREATMENT RESISTANT SCHIZOPHRENIA AND GYRIFICATION-BASED CONNECTOME. Schizophrenia Bulletin, 2018, 44, S373-S373.	2.3	0
89	O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S81-S82.	2.3	0
90	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S238-S238.	2.3	0

#	ARTICLE	IF	CITATIONS
91	T183. LOW LEVELS OF VITAMIN D ARE ASSOCIATED WITH REDUCED CORTICAL THICKNESS AND SURFACE AREA IN FRONTAL, TEMPORAL AND OCCIPITAL REGIONS IN FIRST-EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2020, 46, S301-S302.	2.3	0
92	Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP): A prospective cohort study. Schizophrenia Research, 2022, 246, 26-29.	1.1	0